Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Accounts Payables?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Accounts Payables is 
$412.6M (1Y -55.2% )

ALXN Stock Price & Accounts Payables

Accounts Payables for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Accounts Payables

chevron_right 2021 $118.6M +394x
( +24.8% / year avg)
chevron_left 1995 $300.0K
vertical_align_top Peak $1.9B +6246x
vertical_align_bottom Bottom $300.0K
arrow_drop_up # Up Years 18 18 of 27
years up.
arrow_drop_down # Down Years 9
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.11x the rate relative to it's accounts payables over the same period.
  • If ALXN grows it's stock at the same rate as it's accounts payables (+24.8%/year) , it's stock price will grow +916% and hit $996.45 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 18 years (0%) it's accounts payables were also up.
  • ALXN Historical Accounts Payables Table
    in $ million
    Year Accounts Payables YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $118 -63.7% - -
    4/1/2020 $326 -82.6% - -
    4/1/2019 $1,874 684.5% - -
    4/1/2018 $238 13.2% - -
    4/1/2017 $211 63.3% - -
    4/1/2016 $129 -32.3% - -
    4/1/2015 $190 64.3% - -
    4/1/2014 $116 19.7% - -
    4/1/2013 $97 24.8% - -
    4/1/2012 $77 47.1% - -
    4/1/2011 $52 16.8% - -
    4/1/2010 $45 10.9% - -
    4/1/2009 $40 27.4% - -
    4/1/2008 $32 -16.3% - -
    4/1/2007 $38 241.9% - -
    4/1/2006 $11 -17.6% - -
    4/1/2005 $13 -49.4% - -
    4/1/2004 $26 26.8% - -
    4/1/2003 $21 -28.7% - -
    4/1/2002 $29 302.3% - -
    4/1/2001 $7 -19.2% - -
    4/1/2000 $9 -23.2% - -
    4/1/1999 $11 250.0% - -
    4/1/1998 $3 41.7% - -
    4/1/1997 $2 100.0% - -
    4/1/1996 $1 300.0% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Accounts payable (AP) is an account within the general ledger that represents a company's obligation to pay off a short-term debt to its creditors or suppliers. Another common usage of "AP" refers to the business department or division that is responsible for making payments owed by the company to suppliers and other creditors.

    For more detailed definitions, please see Investopedia.